HealthcarePopulation-scale study highlights ongoing risk of COVID-19 in some...

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

Credit: Pixabay/CC0 Public Domain

A study co-led by the Universities of Oxford, Birmingham and Southampton and the U.K. Health Security Agency (UKHSA), published in Lancet Oncology today by the U.K. Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalization and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

Dr. Lennard Lee, Department of Oncology, University of Oxford who led the study said: “We know that people with have a higher risk of severe COVID-19 disease and that the in following COVID-19 vaccination is lower. However, no study has looked at and its waning in cancer patients at a population level. We have undertaken the largest real-world health system evaluation of COVID-19 in cancer patients globally.”

This study analyzed 377,194 individuals with active or recent cancer who had received two doses of the COVID-19 vaccine and undergone a SARS-CoV-2 PCR test in England. The numbers of breakthrough COVID-19 infections and COVID-19-associated hospitalizations and deaths in this cohort of cancer patients were compared to a control population without active or recent cancer.

The overall vaccine effectiveness against COVID-19 infection in the after two doses of the COVID-19 vaccine over the study period was 69.8% whereas, in the cancer cohort, overall vaccine effectiveness was slightly lower (65.5%). This indicates that COVID-19 vaccination is effective in most cancer patients. However, vaccine effectiveness wanes more quickly in cancer patients. At 3–6 months following the second vaccine dose, vaccine effectiveness reduced by nearly a third from 61.4% in the general population to 47.0% in the cancer cohort.

While the vaccine offers higher protection against COVID-19-associated hospitalization (83.3%) and death (93.4%) than against breakthrough infections in the cancer cohort, this protection also waned by 3–6 months following the second vaccine dose.

Looking at the differences between people with different types of cancer, vaccine effectiveness is lowest and wanes most quickly in those with the blood cancers lymphoma and leukemia.

The type of treatment that people with cancer receive also impacts both overall vaccine effectiveness and waning. In cancer patients that were treated in the last 12 months with chemotherapy or radiotherapy, vaccine effectiveness is lower and waned more by 3–6 months than in cancer patients that did not receive these treatments or were treated more than a year ago.

Professor Peter Johnson, Professor of Medical Oncology, University of Southampton commented: “This study shows that for some people with cancer, COVID-19 vaccination may give less effective and shorter-lasting protection. This highlights the importance of vaccination booster programs and rapid access to COVID-19 treatments for people undergoing cancer treatments.”

Helen Rowntree, Director of Research, Services and Engagement at Blood Cancer U.K. said: “For our community, COVID-19 very much has not gone away and many people remain in their homes due to the threat of COVID-19 highlighted in this important study. We know how important the vaccines are for people with . This study importantly shows that immunity wanes faster in people with blood cancer, who are entitled to five doses, and we’d encourage everyone with blood cancer to make sure they are getting these doses.”

Vaccine protects most cancer patients from COVID, but risk remains higher for patients with blood cancers

More information: … (22)00202-9/fulltext

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination (2022, May 23)
retrieved 24 May 2022

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Original Source Link


Please enter your comment!
Please enter your name here

Latest News

CVS Caremark returns Eliquis to formulary after outcry

CVS Health will return blood thinner Eliquis to its pharmacy benefit manager's commercial formulary beginning July 1, reversing...

Venzo cycling shoes review | Live Science

The Venzo cycling shoe might sport the look of a dad’s running trainer from the ‘90s, but don’t...

Growing affordability gap, racial inequities in housing pose challenges in Houston area, Kinder Institute says

The Kinder Institute of Urban Research has released its 2022 State of Housing report. Original...

Canada To Ban Production, Import Of Single-Use Plastics Starting In December

Canada announced Monday it will ban the production and import of “harmful single-use plastics” starting in December in...

TMNT Goes Back To The ’80s, Chris Hemsworth’s Pitch For Thor In Deadpool 3 & More

Paramount Pictures has been trying to make a "Harbinger" movie for several years now. The potential film would...

Must Read

- Advertisement -

You might also likeRELATED
Recommended to you